Non-oxime pyrazole based inhibitors of B-Raf kinase was written by Newhouse, Bradley J.;Hansen, Joshua D.;Grina, Jonas;Welch, Mike;Topalov, George;Littman, Nicole;Callejo, Michele;Martinson, Matthew;Galbraith, Sarah;Laird, Ellen R.;Brandhuber, Barbara J.;Vigers, Guy;Morales, Tony;Woessner, Rich;Randolph, Nikole;Lyssikatos, Joseph;Olivero, Alan. And the article was included in Bioorganic & Medicinal Chemistry Letters in 2011.Recommanded Product: N-Cbz-7-oxa-3-azabicyclo[4.1.0]heptane This article mentions the following:
The synthesis and biol. evaluation of non-oxime pyrazole based B-Raf inhibitors is reported. Several oxime replacements have been prepared and have shown excellent enzyme activity. Further optimization of fused pyrazole 2a led to compound 38 (I), a selective and potent B-Raf inhibitor. In the experiment, the researchers used many compounds, for example, N-Cbz-7-oxa-3-azabicyclo[4.1.0]heptane (cas: 66207-08-7Recommanded Product: N-Cbz-7-oxa-3-azabicyclo[4.1.0]heptane).
N-Cbz-7-oxa-3-azabicyclo[4.1.0]heptane (cas: 66207-08-7) belongs to piperidine derivatives. Piperidine and its derivatives have become increasingly popular in many synthetic schemes. The piperidine and polyhydroxylated indolizidine derivatives have shown to be promising 伪-glucosidase inhibitors. The former are analogs of DNJ with an improved 伪-glucosidase inhibitory profile than that of DNJ. Boisson et al.Recommanded Product: N-Cbz-7-oxa-3-azabicyclo[4.1.0]heptane
Referemce:
Piperidine – Wikipedia,
Piperidine | C5H11N – PubChem